

Special Issue

Osteoarthritis: Molecular Pathways and Novel Therapeutic Strategies

Message from the Guest Editors

Osteoarthritis (OA) is a prevalent and degenerative joint disorder characterized by the progressive deterioration of joint cartilage and the surrounding structures. It is the most common form of arthritis and often affects weight-bearing joints such as the knees, hips. Osteoarthritis (OA) exhibits a spectrum of clinical phenotypes, reflecting the heterogeneous nature of this prevalent joint disorder: (1) Chronic Pain Phenotype (Emphasizes central mechanisms, such as central sensitization; Characterized by persistent pain, potentially influencing treatment strategies); (2) Inflammatory Phenotype (Marked by elevated levels of inflammatory biomarkers); (3) Metabolic Syndrome Phenotype (Exhibits a high prevalence of obesity, diabetes, and metabolic disturbances); (4) Bone and Cartilage Metabolism Phenotype (Involves alterations in local tissue metabolism); (5) Mechanical Overload Phenotype (Primarily characterized by varus malalignment and medial compartment disease); (6) Minimal Joint Disease Phenotype (Characterized by minor clinical symptoms with slow progression).

Guest Editors

Prof. Dr. Antonia Patrino

Dr. Teresa Paolucci

Dr. Mirko Pesce

Dr. Andrea Pantalone

Deadline for manuscript submissions

closed (20 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/194060

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).